Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$5.26 USD
-0.13 (-2.41%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.25 -0.01 (-0.19%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TVTX 5.26 -0.13(-2.41%)
Will TVTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVTX
Travere (TVTX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
Wall Street Analysts Think Travere (TVTX) Could Surge 66.29%: Read This Before Placing a Bet
Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli
Other News for TVTX
Travere Therapeutics (TVTX) Receives a Hold from Piper Sandler
Buy Rating Affirmed for Travere Therapeutics Following Filspari’s European Approval and Promising US Prospects
Buy Rating Affirmed for Travere Therapeutics on EU Approval and Promising Revenue Projections
Analysts Conflicted on These Healthcare Names: Travere Therapeutics (TVTX), Humana (HUM) and Merck & Company (MRK)
FILSPARI’s European Approval and Market Potential Bolster Buy Rating for Travere Therapeutics